DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025.
Fireside Chat Details
Date & Time: Thursday, September 4, 2025 | 9:10-9:40 am ET
Location: New York Marriott Marquis - 1535 Broadway, New York, NY 10036
Moderator: Joshua Schimmer, Managing Director, Biotech Equity Research Analyst, Cantor Fitzgerald
Webcast: Click here to access the live presentation
Management will also be available for one-on-one meetings with investors during the conference.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902308181/en/
Contacts
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
mhawtin@lifescicomms.com
